Boehringer Ingelheim is accelerating its global pharmacovigilance transformation by leveraging generative AI technologies through LifeSphere® NavaX™, developed by ArisGlobal. The deployment marks a critical step in the company’s broader digital strategy—enabling faster, more accurate, and scalable case intake processes across its safety operations worldwide.
Boehringer Ingelheim deploys ArisGlobal’s LifeSphere® NavaX™ for global safety case intake.
The AI-driven solution delivers up to 90% data extraction accuracy within weeks of implementation.
Reduces manual effort and accelerates ICSR (Individual Case Safety Report) processing.
Enhances operational efficiency and supports strategic safety transformation.
NavaX is powered by GenAI and Dynamic Data Extraction for scalable automation.
Aligns with Boehringer’s vision to build a future-ready pharmacovigilance ecosystem.
Boehringer Ingelheim has implemented LifeSphere NavaX, ArisGlobal’s cognitive engine for pharmacovigilance, as part of its global digital modernization initiative. NavaX leverages Generative AI and Dynamic Data Extraction to process high volumes of ICSR (Individual Case Safety Reports) with high accuracy and minimal human intervention. Within just weeks of deployment, the system achieved an average 90% data extraction accuracy, significantly streamlining manual workflows and expediting safety timelines.
By automating routine case intake and quality control tasks, NavaX empowers safety teams to focus on higher-value responsibilities such as medical reviews and benefit-risk assessments. “With the launch of LifeSphere NavaX, we’re unlocking the potential of AI to process cases faster, more flexibly, and with greater precision,” said Dr. Robert Buchberger, Head of Patient Safety and Pharmacovigilance at Boehringer Ingelheim.
The deployment is aligned with Boehringer’s mission to uphold patient safety while continuously improving the quality and efficiency of its pharmacovigilance operations.
NavaX is part of ArisGlobal’s LifeSphere® Unify platform, providing cognitive automation across safety, regulatory, and clinical functions. Built for life sciences, the platform ensures regulatory compliance while enabling operational agility. “This implementation is a powerful example of how pharma leaders can operationalize GenAI to build intelligent, scalable pharmacovigilance ecosystems,” said Steve Nuckols, Chief Customer Officer at ArisGlobal.
With top pharmaceutical companies now increasingly adopting NavaX, the solution is shaping a new standard for intelligent, automated safety systems across the industry.
Boehringer Ingelheim’s adoption of LifeSphere NavaX reflects a growing shift in the life sciences industry—where GenAI is no longer theoretical, but a practical driver of speed, precision, and future-ready safety transformation.
ArisGlobal, an AI-first technology company and creator of LifeSphere®, is transforming the way today's most successful life sciences companies develop breakthroughs and bring new products to market. Headquartered in the United States, ArisGlobal has regional offices in Europe, India, Japan, and China.
TechIntelPro empowers B2B technology decision-makers with the latest industry trends, deep insights, leadership perspectives and actionable intelligence to drive both organizational and professional milestones—and thrive on the tech pulse.